| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Stroke | 108 | 2024 | 994 | 22.340 |
Why?
|
| Brain Ischemia | 56 | 2025 | 400 | 13.520 |
Why?
|
| Endovascular Procedures | 42 | 2025 | 290 | 10.160 |
Why?
|
| Thrombectomy | 57 | 2025 | 190 | 9.400 |
Why?
|
| Atrial Fibrillation | 15 | 2024 | 357 | 6.050 |
Why?
|
| Intracranial Embolism | 8 | 2022 | 29 | 5.430 |
Why?
|
| Plaque, Atherosclerotic | 8 | 2023 | 60 | 5.320 |
Why?
|
| Thrombolytic Therapy | 24 | 2024 | 241 | 3.700 |
Why?
|
| Neurology | 9 | 2024 | 75 | 3.600 |
Why?
|
| Carotid Artery Diseases | 6 | 2022 | 99 | 3.080 |
Why?
|
| Perfusion Imaging | 6 | 2023 | 50 | 3.000 |
Why?
|
| Humans | 196 | 2025 | 89985 | 2.960 |
Why?
|
| Retrospective Studies | 85 | 2025 | 9216 | 2.690 |
Why?
|
| Arterial Occlusive Diseases | 7 | 2024 | 110 | 2.570 |
Why?
|
| Treatment Outcome | 77 | 2025 | 8277 | 2.550 |
Why?
|
| Aged | 92 | 2025 | 19262 | 2.370 |
Why?
|
| Cerebral Infarction | 11 | 2023 | 72 | 2.230 |
Why?
|
| Fibrinolytic Agents | 16 | 2024 | 227 | 2.220 |
Why?
|
| Carotid Stenosis | 6 | 2024 | 117 | 2.060 |
Why?
|
| Pandemics | 12 | 2024 | 778 | 2.000 |
Why?
|
| Thrombosis | 5 | 2022 | 302 | 1.930 |
Why?
|
| Aged, 80 and over | 55 | 2025 | 6785 | 1.920 |
Why?
|
| Disability Evaluation | 12 | 2024 | 139 | 1.830 |
Why?
|
| Risk Factors | 37 | 2024 | 5562 | 1.780 |
Why?
|
| Venous Thrombosis | 8 | 2024 | 256 | 1.770 |
Why?
|
| Time-to-Treatment | 9 | 2024 | 124 | 1.750 |
Why?
|
| Subarachnoid Hemorrhage | 4 | 2021 | 142 | 1.710 |
Why?
|
| Tomography, X-Ray Computed | 16 | 2025 | 2677 | 1.710 |
Why?
|
| Brain Death | 2 | 2024 | 83 | 1.670 |
Why?
|
| Middle Aged | 79 | 2025 | 26159 | 1.610 |
Why?
|
| Tissue Plasminogen Activator | 11 | 2024 | 173 | 1.590 |
Why?
|
| Foramen Ovale, Patent | 2 | 2022 | 18 | 1.590 |
Why?
|
| Cerebral Veins | 2 | 2022 | 31 | 1.570 |
Why?
|
| Intracranial Thrombosis | 7 | 2024 | 29 | 1.550 |
Why?
|
| Patient Discharge | 6 | 2024 | 326 | 1.540 |
Why?
|
| Cerebrovascular Disorders | 2 | 2024 | 145 | 1.500 |
Why?
|
| Female | 95 | 2025 | 46602 | 1.500 |
Why?
|
| Male | 92 | 2025 | 42690 | 1.480 |
Why?
|
| Brain Injuries | 2 | 2023 | 166 | 1.480 |
Why?
|
| Carotid Arteries | 6 | 2024 | 135 | 1.430 |
Why?
|
| Intracranial Hemorrhages | 17 | 2024 | 130 | 1.390 |
Why?
|
| Nervous System Diseases | 5 | 2021 | 163 | 1.340 |
Why?
|
| Cerebral Hemorrhage | 9 | 2024 | 341 | 1.330 |
Why?
|
| Registries | 16 | 2024 | 808 | 1.320 |
Why?
|
| Nervous System | 4 | 2013 | 90 | 1.320 |
Why?
|
| Stroke Rehabilitation | 3 | 2021 | 42 | 1.290 |
Why?
|
| Anticoagulants | 8 | 2024 | 432 | 1.240 |
Why?
|
| Computed Tomography Angiography | 8 | 2024 | 155 | 1.240 |
Why?
|
| Editorial Policies | 3 | 2023 | 34 | 1.240 |
Why?
|
| Dementia | 2 | 2023 | 203 | 1.160 |
Why?
|
| Time Factors | 22 | 2024 | 5358 | 1.100 |
Why?
|
| Brain | 8 | 2024 | 2306 | 1.090 |
Why?
|
| Vertebral Artery Dissection | 4 | 2024 | 14 | 1.090 |
Why?
|
| Platelet Aggregation Inhibitors | 8 | 2024 | 147 | 1.060 |
Why?
|
| Meningoencephalitis | 2 | 2023 | 9 | 1.050 |
Why?
|
| Practice Patterns, Physicians' | 4 | 2024 | 608 | 1.040 |
Why?
|
| Risk Assessment | 14 | 2024 | 2327 | 1.010 |
Why?
|
| Sleep | 3 | 2024 | 455 | 1.010 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 319 | 0.990 |
Why?
|
| Neuroimaging | 5 | 2023 | 116 | 0.990 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 305 | 0.990 |
Why?
|
| Cohort Studies | 16 | 2024 | 2886 | 0.970 |
Why?
|
| Reperfusion | 2 | 2024 | 32 | 0.950 |
Why?
|
| Posterior Leukoencephalopathy Syndrome | 2 | 2021 | 13 | 0.950 |
Why?
|
| Cerebellar Diseases | 1 | 2024 | 21 | 0.950 |
Why?
|
| Anti-N-Methyl-D-Aspartate Receptor Encephalitis | 1 | 2024 | 8 | 0.950 |
Why?
|
| Hospital Mortality | 9 | 2024 | 408 | 0.950 |
Why?
|
| Comorbidity | 4 | 2024 | 953 | 0.940 |
Why?
|
| Neurologists | 1 | 2024 | 7 | 0.930 |
Why?
|
| Aphasia | 1 | 2024 | 15 | 0.920 |
Why?
|
| Embolism | 3 | 2024 | 33 | 0.910 |
Why?
|
| Severity of Illness Index | 10 | 2024 | 1862 | 0.900 |
Why?
|
| Meningitis, Cryptococcal | 1 | 2023 | 2 | 0.900 |
Why?
|
| Drug Resistant Epilepsy | 1 | 2024 | 51 | 0.890 |
Why?
|
| Myositis, Inclusion Body | 1 | 2023 | 2 | 0.890 |
Why?
|
| Hypoxia-Ischemia, Brain | 1 | 2024 | 52 | 0.890 |
Why?
|
| Cerebral Palsy | 1 | 2024 | 97 | 0.890 |
Why?
|
| Emergency Service, Hospital | 4 | 2023 | 529 | 0.880 |
Why?
|
| Databases, Factual | 3 | 2024 | 866 | 0.880 |
Why?
|
| Muscular Dystrophies, Limb-Girdle | 1 | 2023 | 15 | 0.850 |
Why?
|
| Status Epilepticus | 1 | 2023 | 39 | 0.850 |
Why?
|
| Mitochondrial Diseases | 1 | 2023 | 12 | 0.840 |
Why?
|
| Gray Matter | 1 | 2023 | 35 | 0.830 |
Why?
|
| Independent Living | 1 | 2023 | 21 | 0.830 |
Why?
|
| Virus Diseases | 1 | 2023 | 99 | 0.830 |
Why?
|
| Hypoxia, Brain | 1 | 2023 | 43 | 0.830 |
Why?
|
| Sleep Apnea Syndromes | 1 | 2024 | 107 | 0.830 |
Why?
|
| Epilepsy, Temporal Lobe | 1 | 2024 | 132 | 0.830 |
Why?
|
| Carotid Artery, Internal | 2 | 2020 | 69 | 0.810 |
Why?
|
| Disease Progression | 7 | 2017 | 1469 | 0.800 |
Why?
|
| Intracranial Arteriosclerosis | 1 | 2022 | 55 | 0.790 |
Why?
|
| Multiple Sclerosis | 1 | 2024 | 274 | 0.790 |
Why?
|
| Consensus | 1 | 2024 | 366 | 0.790 |
Why?
|
| Cognitive Dysfunction | 1 | 2024 | 155 | 0.780 |
Why?
|
| Glucocorticoids | 1 | 2024 | 357 | 0.770 |
Why?
|
| Adult | 33 | 2024 | 26827 | 0.760 |
Why?
|
| Predictive Value of Tests | 10 | 2024 | 1732 | 0.760 |
Why?
|
| Clinical Trials as Topic | 2 | 2024 | 1134 | 0.760 |
Why?
|
| Prospective Studies | 12 | 2024 | 4329 | 0.760 |
Why?
|
| Miller Fisher Syndrome | 1 | 2020 | 1 | 0.730 |
Why?
|
| Neuritis | 1 | 2020 | 8 | 0.720 |
Why?
|
| Cranial Nerve Diseases | 1 | 2020 | 8 | 0.720 |
Why?
|
| Ophthalmoplegia | 1 | 2020 | 11 | 0.720 |
Why?
|
| Basilar Artery | 4 | 2024 | 42 | 0.720 |
Why?
|
| Betacoronavirus | 2 | 2020 | 262 | 0.710 |
Why?
|
| Prevalence | 5 | 2024 | 1250 | 0.710 |
Why?
|
| Thrombocytopenia | 1 | 2021 | 187 | 0.690 |
Why?
|
| Patient Transfer | 1 | 2021 | 99 | 0.690 |
Why?
|
| Vaccines | 1 | 2021 | 84 | 0.690 |
Why?
|
| Precision Medicine | 1 | 2024 | 413 | 0.670 |
Why?
|
| Hyoid Bone | 1 | 2019 | 12 | 0.660 |
Why?
|
| Interdisciplinary Communication | 2 | 2017 | 131 | 0.660 |
Why?
|
| Perceptual Disorders | 1 | 2019 | 12 | 0.660 |
Why?
|
| Intracranial Aneurysm | 2 | 2021 | 178 | 0.660 |
Why?
|
| Paresis | 1 | 2019 | 15 | 0.660 |
Why?
|
| Hospitalization | 8 | 2023 | 888 | 0.660 |
Why?
|
| Hair | 1 | 2019 | 56 | 0.640 |
Why?
|
| Carotid Artery, Internal, Dissection | 5 | 2024 | 23 | 0.640 |
Why?
|
| Mitochondria | 1 | 2023 | 556 | 0.640 |
Why?
|
| Heart Defects, Congenital | 1 | 2022 | 365 | 0.640 |
Why?
|
| Spasm | 1 | 2018 | 17 | 0.610 |
Why?
|
| Inpatients | 5 | 2024 | 312 | 0.610 |
Why?
|
| United States | 16 | 2024 | 7114 | 0.590 |
Why?
|
| Cerebrovascular Circulation | 1 | 2019 | 232 | 0.580 |
Why?
|
| Efficiency, Organizational | 1 | 2017 | 59 | 0.570 |
Why?
|
| Erythrocyte Indices | 1 | 2017 | 9 | 0.560 |
Why?
|
| Sinus Thrombosis, Intracranial | 3 | 2024 | 14 | 0.560 |
Why?
|
| Recovery of Function | 7 | 2024 | 298 | 0.560 |
Why?
|
| Magnetic Resonance Imaging | 8 | 2024 | 3477 | 0.550 |
Why?
|
| Stents | 6 | 2024 | 412 | 0.550 |
Why?
|
| Motion Pictures | 1 | 2016 | 11 | 0.550 |
Why?
|
| Medical Staff, Hospital | 1 | 2017 | 109 | 0.540 |
Why?
|
| Delivery of Health Care | 1 | 2021 | 437 | 0.530 |
Why?
|
| Demyelinating Diseases | 1 | 2016 | 67 | 0.530 |
Why?
|
| Aspergillosis | 1 | 2016 | 41 | 0.520 |
Why?
|
| Age Factors | 6 | 2024 | 1880 | 0.520 |
Why?
|
| Malnutrition | 1 | 2016 | 33 | 0.520 |
Why?
|
| Medulla Oblongata | 1 | 2016 | 93 | 0.520 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2016 | 81 | 0.520 |
Why?
|
| Functional Laterality | 1 | 2016 | 199 | 0.510 |
Why?
|
| Blood Pressure | 4 | 2020 | 906 | 0.510 |
Why?
|
| Brain Concussion | 1 | 2016 | 65 | 0.510 |
Why?
|
| Time Management | 1 | 2015 | 9 | 0.490 |
Why?
|
| Factor VIII | 1 | 2015 | 7 | 0.490 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2015 | 40 | 0.480 |
Why?
|
| Brain Infarction | 1 | 2015 | 23 | 0.480 |
Why?
|
| Administration, Intravenous | 4 | 2024 | 56 | 0.480 |
Why?
|
| Rehabilitation Centers | 1 | 2013 | 8 | 0.450 |
Why?
|
| Vertebrobasilar Insufficiency | 2 | 2024 | 18 | 0.450 |
Why?
|
| Patient Care | 1 | 2015 | 102 | 0.450 |
Why?
|
| Biomarkers | 5 | 2024 | 1778 | 0.440 |
Why?
|
| Chronic Pain | 1 | 2016 | 165 | 0.440 |
Why?
|
| Magnesium | 1 | 2013 | 178 | 0.420 |
Why?
|
| Infarction | 2 | 2022 | 27 | 0.410 |
Why?
|
| Internship and Residency | 3 | 2017 | 1063 | 0.410 |
Why?
|
| Japan | 2 | 2023 | 304 | 0.400 |
Why?
|
| Glucose | 1 | 2015 | 629 | 0.400 |
Why?
|
| Mechanical Thrombolysis | 4 | 2024 | 16 | 0.390 |
Why?
|
| Cross-Sectional Studies | 9 | 2024 | 1731 | 0.380 |
Why?
|
| Analgesics, Opioid | 1 | 2016 | 451 | 0.380 |
Why?
|
| Logistic Models | 8 | 2016 | 1214 | 0.380 |
Why?
|
| Eligibility Determination | 2 | 2022 | 36 | 0.360 |
Why?
|
| Child | 4 | 2024 | 7242 | 0.360 |
Why?
|
| Aspirin | 2 | 2024 | 162 | 0.360 |
Why?
|
| Decision Making | 1 | 2016 | 671 | 0.350 |
Why?
|
| Prognosis | 10 | 2024 | 3800 | 0.350 |
Why?
|
| Blood Glucose | 3 | 2024 | 837 | 0.330 |
Why?
|
| Surveys and Questionnaires | 6 | 2024 | 2657 | 0.320 |
Why?
|
| Anesthesia, General | 3 | 2025 | 116 | 0.320 |
Why?
|
| National Institutes of Health (U.S.) | 3 | 2021 | 125 | 0.320 |
Why?
|
| Echocardiography, Transesophageal | 3 | 2021 | 348 | 0.310 |
Why?
|
| Societies, Medical | 2 | 2024 | 584 | 0.310 |
Why?
|
| Propensity Score | 3 | 2024 | 149 | 0.310 |
Why?
|
| Hemorrhage | 3 | 2024 | 287 | 0.300 |
Why?
|
| Coronary Artery Disease | 1 | 2012 | 367 | 0.300 |
Why?
|
| Longitudinal Studies | 2 | 2023 | 1082 | 0.290 |
Why?
|
| Odds Ratio | 6 | 2016 | 682 | 0.280 |
Why?
|
| Chi-Square Distribution | 5 | 2016 | 358 | 0.280 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2024 | 841 | 0.280 |
Why?
|
| Patient Selection | 2 | 2019 | 682 | 0.250 |
Why?
|
| Electroencephalography | 2 | 2023 | 757 | 0.240 |
Why?
|
| Fatal Outcome | 2 | 2016 | 296 | 0.240 |
Why?
|
| Administration, Oral | 2 | 2023 | 667 | 0.240 |
Why?
|
| Warfarin | 2 | 2024 | 104 | 0.240 |
Why?
|
| Constriction, Pathologic | 2 | 2023 | 222 | 0.240 |
Why?
|
| Neurologic Examination | 3 | 2013 | 120 | 0.240 |
Why?
|
| Hemispherectomy | 1 | 2024 | 3 | 0.240 |
Why?
|
| Infarction, Posterior Cerebral Artery | 1 | 2024 | 1 | 0.240 |
Why?
|
| Incidence | 3 | 2024 | 1604 | 0.230 |
Why?
|
| Alberta | 2 | 2024 | 8 | 0.230 |
Why?
|
| Cross Infection | 3 | 2015 | 151 | 0.230 |
Why?
|
| Infarction, Middle Cerebral Artery | 2 | 2024 | 40 | 0.230 |
Why?
|
| Travel | 1 | 2024 | 72 | 0.220 |
Why?
|
| Conscious Sedation | 1 | 2024 | 69 | 0.220 |
Why?
|
| Sex Factors | 3 | 2023 | 1075 | 0.220 |
Why?
|
| Leukocytosis | 2 | 2014 | 16 | 0.220 |
Why?
|
| Neuromyelitis Optica | 1 | 2023 | 22 | 0.220 |
Why?
|
| Venous Thromboembolism | 2 | 2024 | 161 | 0.220 |
Why?
|
| Blood Coagulation | 1 | 2023 | 91 | 0.220 |
Why?
|
| Treatment Refusal | 1 | 2023 | 62 | 0.220 |
Why?
|
| Medically Uninsured | 1 | 2023 | 64 | 0.220 |
Why?
|
| Seizures | 2 | 2023 | 307 | 0.210 |
Why?
|
| Elective Surgical Procedures | 1 | 2024 | 129 | 0.210 |
Why?
|
| Arousal | 1 | 2023 | 170 | 0.210 |
Why?
|
| Developed Countries | 1 | 2022 | 25 | 0.210 |
Why?
|
| Young Adult | 9 | 2020 | 6415 | 0.210 |
Why?
|
| Cysts | 1 | 2023 | 106 | 0.210 |
Why?
|
| Patients | 1 | 2023 | 102 | 0.210 |
Why?
|
| Educational Status | 1 | 2023 | 195 | 0.200 |
Why?
|
| Anticonvulsants | 1 | 2023 | 126 | 0.200 |
Why?
|
| Whole Genome Sequencing | 1 | 2023 | 103 | 0.200 |
Why?
|
| Length of Stay | 3 | 2020 | 749 | 0.200 |
Why?
|
| Forecasting | 1 | 2023 | 304 | 0.200 |
Why?
|
| Dabigatran | 1 | 2022 | 25 | 0.200 |
Why?
|
| Hematoma | 2 | 2023 | 108 | 0.200 |
Why?
|
| Disease Management | 1 | 2024 | 327 | 0.190 |
Why?
|
| Drug Therapy, Combination | 1 | 2024 | 785 | 0.190 |
Why?
|
| Recurrence | 3 | 2024 | 1145 | 0.190 |
Why?
|
| Perfusion | 1 | 2023 | 253 | 0.190 |
Why?
|
| Cognition | 2 | 2023 | 580 | 0.190 |
Why?
|
| New Jersey | 1 | 2021 | 4 | 0.190 |
Why?
|
| Headache | 2 | 2023 | 73 | 0.190 |
Why?
|
| Hypokinesia | 1 | 2021 | 3 | 0.190 |
Why?
|
| Clinical Decision-Making | 1 | 2023 | 281 | 0.190 |
Why?
|
| Autoimmune Diseases | 1 | 2023 | 250 | 0.190 |
Why?
|
| Hospitals | 1 | 2023 | 303 | 0.180 |
Why?
|
| Neuropsychological Tests | 1 | 2023 | 506 | 0.180 |
Why?
|
| Tobacco Use | 1 | 2020 | 27 | 0.180 |
Why?
|
| Benchmarking | 1 | 2021 | 79 | 0.180 |
Why?
|
| Lymphocyte Count | 1 | 2020 | 99 | 0.180 |
Why?
|
| Epilepsy | 1 | 2024 | 424 | 0.180 |
Why?
|
| Feeding Behavior | 1 | 2023 | 328 | 0.180 |
Why?
|
| Health Services Accessibility | 1 | 2024 | 437 | 0.180 |
Why?
|
| Terminology as Topic | 2 | 2012 | 222 | 0.170 |
Why?
|
| Hypotension | 1 | 2020 | 71 | 0.170 |
Why?
|
| Arterial Pressure | 1 | 2020 | 38 | 0.170 |
Why?
|
| Preoperative Period | 1 | 2020 | 94 | 0.170 |
Why?
|
| Rivaroxaban | 1 | 2019 | 12 | 0.170 |
Why?
|
| Automation | 1 | 2020 | 112 | 0.170 |
Why?
|
| Global Health | 1 | 2021 | 193 | 0.160 |
Why?
|
| Decision Support Techniques | 2 | 2024 | 168 | 0.160 |
Why?
|
| Cerebral Cortex | 1 | 2023 | 591 | 0.160 |
Why?
|
| Secondary Prevention | 1 | 2019 | 159 | 0.160 |
Why?
|
| Physical Examination | 1 | 2019 | 149 | 0.150 |
Why?
|
| Infant, Newborn | 1 | 2024 | 2497 | 0.150 |
Why?
|
| Aging | 1 | 2023 | 727 | 0.150 |
Why?
|
| Physician-Nurse Relations | 1 | 2017 | 2 | 0.150 |
Why?
|
| Upper Extremity | 1 | 2018 | 53 | 0.150 |
Why?
|
| Leukoencephalopathy, Progressive Multifocal | 1 | 2017 | 13 | 0.140 |
Why?
|
| Artifacts | 1 | 2019 | 246 | 0.140 |
Why?
|
| Brain Stem Infarctions | 1 | 2017 | 5 | 0.140 |
Why?
|
| Nursing Staff, Hospital | 1 | 2017 | 42 | 0.140 |
Why?
|
| Child, Preschool | 1 | 2024 | 3773 | 0.140 |
Why?
|
| Pancytopenia | 1 | 2017 | 23 | 0.140 |
Why?
|
| Cerebral Intraventricular Hemorrhage | 1 | 2016 | 10 | 0.140 |
Why?
|
| Multivariate Analysis | 3 | 2016 | 983 | 0.140 |
Why?
|
| Practice Guidelines as Topic | 1 | 2024 | 1055 | 0.140 |
Why?
|
| ROC Curve | 3 | 2016 | 778 | 0.140 |
Why?
|
| Decompressive Craniectomy | 1 | 2016 | 19 | 0.140 |
Why?
|
| Computer Security | 1 | 2016 | 17 | 0.140 |
Why?
|
| Osmotic Pressure | 1 | 2016 | 21 | 0.140 |
Why?
|
| Inventions | 1 | 2016 | 13 | 0.140 |
Why?
|
| Angiography, Digital Subtraction | 1 | 2016 | 99 | 0.130 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2016 | 68 | 0.130 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2017 | 91 | 0.130 |
Why?
|
| White Matter | 1 | 2017 | 85 | 0.130 |
Why?
|
| Smartphone | 1 | 2016 | 41 | 0.130 |
Why?
|
| Cardiomegaly | 1 | 2016 | 120 | 0.130 |
Why?
|
| Wakefulness | 1 | 2016 | 135 | 0.130 |
Why?
|
| Phenotype | 1 | 2022 | 2457 | 0.130 |
Why?
|
| Viral Load | 1 | 2016 | 145 | 0.130 |
Why?
|
| History, 21st Century | 1 | 2016 | 185 | 0.130 |
Why?
|
| Outpatients | 1 | 2016 | 101 | 0.130 |
Why?
|
| Meningeal Carcinomatosis | 1 | 2015 | 7 | 0.130 |
Why?
|
| Pneumonia | 2 | 2021 | 183 | 0.130 |
Why?
|
| Area Under Curve | 2 | 2015 | 338 | 0.120 |
Why?
|
| History, 20th Century | 1 | 2016 | 315 | 0.120 |
Why?
|
| Heart Atria | 1 | 2016 | 282 | 0.120 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2017 | 300 | 0.120 |
Why?
|
| Diagnosis, Differential | 2 | 2017 | 1606 | 0.120 |
Why?
|
| Follow-Up Studies | 4 | 2022 | 3678 | 0.110 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2016 | 275 | 0.110 |
Why?
|
| Medical Errors | 1 | 2015 | 115 | 0.110 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2020 | 1255 | 0.110 |
Why?
|
| Intubation, Gastrointestinal | 1 | 2013 | 31 | 0.110 |
Why?
|
| Quality Improvement | 1 | 2017 | 457 | 0.110 |
Why?
|
| Ticlopidine | 1 | 2013 | 25 | 0.110 |
Why?
|
| Community-Acquired Infections | 1 | 2013 | 65 | 0.110 |
Why?
|
| Patient Admission | 1 | 2013 | 114 | 0.110 |
Why?
|
| Opioid-Related Disorders | 1 | 2016 | 193 | 0.110 |
Why?
|
| Acute Disease | 1 | 2015 | 846 | 0.100 |
Why?
|
| Deglutition Disorders | 1 | 2013 | 119 | 0.100 |
Why?
|
| Down-Regulation | 1 | 2013 | 521 | 0.100 |
Why?
|
| Iran | 2 | 2021 | 15 | 0.090 |
Why?
|
| Sex Characteristics | 2 | 2024 | 328 | 0.090 |
Why?
|
| Echocardiography | 1 | 2016 | 944 | 0.090 |
Why?
|
| Attitude of Health Personnel | 1 | 2016 | 654 | 0.090 |
Why?
|
| Adolescent | 3 | 2023 | 9345 | 0.090 |
Why?
|
| Personnel Staffing and Scheduling | 1 | 2011 | 96 | 0.090 |
Why?
|
| Postoperative Complications | 1 | 2020 | 2314 | 0.090 |
Why?
|
| Blood Pressure Determination | 2 | 2020 | 60 | 0.080 |
Why?
|
| Continuity of Patient Care | 1 | 2011 | 172 | 0.080 |
Why?
|
| Case-Control Studies | 2 | 2024 | 1866 | 0.080 |
Why?
|
| Neoplasms | 1 | 2024 | 3067 | 0.080 |
Why?
|
| Infusions, Intravenous | 2 | 2021 | 416 | 0.080 |
Why?
|
| Sex Distribution | 2 | 2021 | 171 | 0.070 |
Why?
|
| Internationality | 1 | 2024 | 70 | 0.060 |
Why?
|
| Heparin, Low-Molecular-Weight | 1 | 2024 | 30 | 0.060 |
Why?
|
| Catheters | 1 | 2024 | 85 | 0.060 |
Why?
|
| Middle Cerebral Artery | 1 | 2024 | 21 | 0.060 |
Why?
|
| Reproducibility of Results | 2 | 2024 | 2769 | 0.060 |
Why?
|
| Aquaporin 4 | 1 | 2023 | 8 | 0.060 |
Why?
|
| Posterior Cerebral Artery | 1 | 2023 | 2 | 0.050 |
Why?
|
| Treatment Failure | 1 | 2024 | 278 | 0.050 |
Why?
|
| Cerebral Angiography | 1 | 2024 | 197 | 0.050 |
Why?
|
| Delayed Diagnosis | 1 | 2023 | 34 | 0.050 |
Why?
|
| Rare Diseases | 1 | 2023 | 69 | 0.050 |
Why?
|
| Observational Studies as Topic | 1 | 2023 | 50 | 0.050 |
Why?
|
| Hyperglycemia | 1 | 2024 | 172 | 0.050 |
Why?
|
| Arteries | 1 | 2024 | 179 | 0.050 |
Why?
|
| Antibodies, Antiphospholipid | 1 | 2022 | 10 | 0.050 |
Why?
|
| Intention to Treat Analysis | 1 | 2022 | 72 | 0.050 |
Why?
|
| Anesthesia | 1 | 2025 | 169 | 0.050 |
Why?
|
| Punctures | 1 | 2022 | 30 | 0.050 |
Why?
|
| Drug Administration Schedule | 1 | 2024 | 864 | 0.050 |
Why?
|
| Glycoproteins | 1 | 2023 | 235 | 0.050 |
Why?
|
| Neurosurgical Procedures | 1 | 2024 | 243 | 0.050 |
Why?
|
| Angioplasty | 1 | 2022 | 70 | 0.050 |
Why?
|
| Workflow | 1 | 2022 | 81 | 0.050 |
Why?
|
| Feasibility Studies | 1 | 2024 | 785 | 0.050 |
Why?
|
| Egypt | 1 | 2021 | 13 | 0.050 |
Why?
|
| Cranial Sinuses | 1 | 2021 | 15 | 0.050 |
Why?
|
| Hospitals, Low-Volume | 1 | 2021 | 19 | 0.050 |
Why?
|
| Consciousness Disorders | 1 | 2021 | 10 | 0.050 |
Why?
|
| Spain | 1 | 2021 | 32 | 0.050 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 1 | 2021 | 29 | 0.050 |
Why?
|
| Cost-Benefit Analysis | 1 | 2023 | 467 | 0.050 |
Why?
|
| Hospitals, High-Volume | 1 | 2021 | 38 | 0.050 |
Why?
|
| Interrupted Time Series Analysis | 1 | 2020 | 8 | 0.050 |
Why?
|
| Europe | 1 | 2021 | 324 | 0.050 |
Why?
|
| Vision Disorders | 1 | 2021 | 75 | 0.040 |
Why?
|
| Combined Modality Therapy | 1 | 2024 | 1704 | 0.040 |
Why?
|
| Latin America | 1 | 2019 | 14 | 0.040 |
Why?
|
| Stroke Volume | 1 | 2022 | 479 | 0.040 |
Why?
|
| Vascular Diseases | 1 | 2020 | 118 | 0.040 |
Why?
|
| Factor Xa Inhibitors | 1 | 2019 | 23 | 0.040 |
Why?
|
| Mobility Limitation | 1 | 2019 | 19 | 0.040 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2019 | 64 | 0.040 |
Why?
|
| Bayes Theorem | 1 | 2020 | 382 | 0.040 |
Why?
|
| Critical Illness | 1 | 2021 | 311 | 0.040 |
Why?
|
| Critical Care | 1 | 2021 | 384 | 0.040 |
Why?
|
| Late Onset Disorders | 1 | 2017 | 3 | 0.040 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2019 | 244 | 0.040 |
Why?
|
| Health Status | 1 | 2019 | 371 | 0.030 |
Why?
|
| Louisiana | 1 | 2016 | 18 | 0.030 |
Why?
|
| Demography | 1 | 2016 | 183 | 0.030 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2022 | 1355 | 0.030 |
Why?
|
| Hodgkin Disease | 1 | 2017 | 181 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2019 | 1714 | 0.030 |
Why?
|
| Animals | 1 | 2015 | 27536 | 0.030 |
Why?
|
| Monitoring, Ambulatory | 1 | 2015 | 32 | 0.030 |
Why?
|
| Pregnancy | 1 | 2022 | 3046 | 0.030 |
Why?
|
| Observer Variation | 1 | 2015 | 614 | 0.030 |
Why?
|
| Hypertension | 1 | 2019 | 747 | 0.030 |
Why?
|
| Ischemic Attack, Transient | 1 | 2015 | 182 | 0.030 |
Why?
|
| Health Personnel | 1 | 2015 | 214 | 0.030 |
Why?
|
| Gastrostomy | 1 | 2013 | 70 | 0.030 |
Why?
|
| Enteral Nutrition | 1 | 2013 | 105 | 0.030 |
Why?
|